XBiotech to develop human antibody combination as candidate treatment for influenza-COVID-19 co-infection
On Sept. 21, 2020, XBiotech announced it was developing a new breakthrough candidate therapy it calls FLUVID for…
Lilly and Amgen announced manufacturing collaboration for COVID-19 antibody therapies
On Sept. 17, 2020, Eli Lilly and Amgen announced a global antibody manufacturing collaboration to significantly increase the…
AXIM Biotechnologies filed Emergency Use Authorization with COVID-19 rapid diagnostic test for neutralizing antibodies
On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
Soligenix announced publication demonstrating thermostabilization of filovirus vaccine antigens
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
Mateon global study for Artemisinin intervention against COVID-19 cleared for patient enrollment in India
On Sept. 14, 2020, Mateon Therapeutics announced that its global study based on its ARTI-19 protocol for Artemisinin…
Baricitinib in combination with remdesivir reduced time to recovery in hospitalized patients with COVID-19 in ACTT-2 Trial
On Sept. 14, 2020, Eli Lilly and Incyte announced initial data from the Adaptive COVID-19 Treatment Trial (ACTT-2)…
Pascal Biosciences and SoRSE Technology announced partnership for cannabinoid drug development and cancer clinical trials
On Sept. 14, 2020, Pascal Biosciences and SoRSE Technology announced they had entered into a collaborative research agreement…
NIH augmented large scale study of Alzheimer’s disease biomarkers
On Sept. 10, 2020, the NIH announced that it had added funding for more biomarker measures, including positron…
Biology | Biotechnology | COVID-19 | Diagnostics | Disease | Infectious Disease | Life Science News | Oncology | Therapeutics
NanoString announced new GeoMx COVID-19 Consortium, part of the GeoMx Translational Leadership Network
On Sept. 9, 2020, NanoString Technologies announced the formation of the GeoMx Translational Leadership Network (GTLN). The GTLN…
FDA approved Trelegy Ellipta as first once-daily single inhaler triple therapy for treatment of both asthma and COPD in the U.S.
On Sept. 10, 2020, GlaxoSmithKline and Innoviva announced the U.S. Food and Drug Administration (FDA) had approved a…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Life Science News | Therapeutics | Vaccine
Biopharma leaders united to stand with science
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
RedHill Biopharma’s opaganib demonstrated complete inhibition of SARS-CoV-2
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Medicine | Non-Profit Research | Stem Cell | Therapeutics
California’s Stem Cell Agency and the Chan Zuckerberg Initiative partnered to create COVID-19 database
On Sept. 8, 2020, a new collaboration between the California Institute for Regenerative Medicine (CIRM) and the Chan…
UT Southwestern researchers showed how mutations in DNA packaging machines cause cancer
On Sept. 7, 2020, research from the Children’s Medical Center Research Institute at UT Southwestern (CRI) determined how…
RedHill Biopharma’s Opaganib awarded COVID-19 grant by State of Pennsylvania
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
Lenzilumab COVID-19 case-control study published in Mayo Clinic Proceedings Journal
On Sept. 3, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80%…
U.S. Government exercised option to purchase additional RAPIVAB from BioCryst for delivery to Strategic National Stockpile
On Sept. 3, 2020, BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services (HHS) had…
Mesoblast announced first patients dosed in phase 2/3 trial for COVID-19 ARDS
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
Janssen discontinued Pimodivir influenza development program
On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…
Titers of antibodies against SARS-CoV2 did not decline within four months
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
COVID-19 | Disease | FDA | Therapeutics
City of Hope doctors lead novel clinical trial to treat cancer patients with COVID-19
On Sept. 1, 2020, City of Hope announced that it was investigating an innovative treatment for cancer patients…
Sanofi updated Kevzara (sarilumab) phase 3 trial in severe and critically ill COVID-19 patients outside the US
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
Novavax and Canada reached agreement to acquire Novavax COVID-19 vaccine
On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada…
NIAID awarded BioCryst $44 million contract to advance development of galidesivir
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
RedHill Biopharma Announced Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
Laurent Pharmaceuticals received FDA approval to initiate its COVID-19 phase 2 clinical trial in the U.S.
On Aug. 27, 2020, Laurent Pharmaceuticals announced that it had received approval from the U.S. Food and Drug…
Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19
On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory….
Assembly Biosciences and Arbutus announced collaboration to evaluate combination of core inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in patients with Chronic Hepatitis B Virus Infection
On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…
How SARS-CoV-2 spread across greater Boston during pandemic’s first wave
On Aug. 25, 2020, data from the Broad Institute of MIT and Harvard, Massachusetts General Hospital, the Massachusetts…
CytoDyn reached enrollment of 195 patients in its phase 3 trial for COVID-19 patients with severe-to-critical symptoms
On Aug. 25, 2020, CytoDyn announced the Company had reached the requisite number of enrolled patients in its…